End-Stage Renal Disease Clinical Trial
Official title:
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes (BRAVO)
The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties). The investigators will also examine intervention practices to identify components that best support engagement and sustainability.
Approximately 35,000 Veterans have end stage kidney disease (ESKD) with an incidence of 13,000 annually. These numbers are increasing because of the epidemic of diabetes, the most common cause of ESKD, among the Veteran population. Patients with ESKD on hemodialysis have substantial cardiovascular morbidity. Veterans annual mortality is in excess of 15% and more than half the deaths are due to cardiovascular disease. Beta blockers have been shown to prevent cardiovascular events in randomized clinical trials in patients without chronic kidney disease, particularly those with heart failure and after myocardial infarction. Beta blockers are a mainstay of therapy in dialysis patients, with two-thirds of Veterans on dialysis receiving a beta blocker. There are no head-to-head randomized studies comparing the two most commonly used beta blockers in ESKD patients in the United States, metoprolol and carvedilol, but observational studies suggest superior outcomes for patients treated with metoprolol. The identification of the superior beta blocker may significantly improve the morbidity and mortality of the VA dialysis population. The investigators aim to compare two beta blockers with similar indications, usage and availability within the VA but with major differences in patients dialysis clearance and adrenergic effects. The investigators aim to determine if patients undergoing dialysis have improved survival when using metoprolol succinate, a beta blocker that is removed by dialysis and is beta-1 selective, compared to carvedilol, a beta blocker that is not removed by dialysis and is not beta-selective and is also an alpha-blocker. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04087213 -
Study of HemoCare™ Hemodialysis System for Home Nocturnal Dialysis in Patients With ESRD
|
N/A | |
| Completed |
NCT02207088 -
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
|
Phase 3 | |
| Not yet recruiting |
NCT03090828 -
Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease
|
N/A | |
| Completed |
NCT02237521 -
The Effect of the Incretin Hormones on the Endocrine Pancreatic Function During Hyperglycemia in End-stage Renal Disease
|
N/A | |
| Withdrawn |
NCT01691196 -
Inflammation in Peritoneal Dialysis Patients: Effect of Obesity
|
||
| Completed |
NCT01394341 -
Liraglutide Treatment to Patients With Severe Renal Insufficiency
|
Phase 4 | |
| Active, not recruiting |
NCT00247507 -
The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients
|
Phase 4 | |
| Completed |
NCT00307463 -
Effects of Strict Volume Control in Hypertensive Hemodialysis Patients on Cardiac Structure and Chronic Inflammation
|
Phase 4 | |
| Recruiting |
NCT00155363 -
Effect of Different Hemodialysis Modality on Adiponectin,Vascular Function and Clinical Prognosis
|
Phase 4 | |
| Completed |
NCT00234156 -
The Effect of Fructose on Blood Fats in Dialysis Patients and Healthy Volunteers
|
N/A | |
| Completed |
NCT00586131 -
Arterial pH and Total Body Nitrogen Balances in APD
|
Phase 4 | |
| Active, not recruiting |
NCT05027074 -
Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
|
Phase 2 | |
| Recruiting |
NCT04575077 -
The Role of Hepcidin as a Biomarker to Predict Successful Renal Transplantation
|
||
| Enrolling by invitation |
NCT05001009 -
Goals of Care Conversations Study
|
N/A | |
| Completed |
NCT01756508 -
Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury
|
Phase 2 | |
| Recruiting |
NCT03862859 -
The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis
|
Phase 4 | |
| Terminated |
NCT03661229 -
Cardiovascular and Respiratory Assessment Using Biometric Signals in a Non-contact Monitoring Device
|
N/A | |
| Completed |
NCT03288922 -
Protein-bound Toxin Removal Between Limited Blood Flow Super High-flux Online HDF and High-Efficiency Online HDF
|
N/A | |
| Completed |
NCT02572882 -
Gut Microbiome and p-Inulin in Hemodialysis
|
N/A | |
| Completed |
NCT02360748 -
A Plant Based High Protein Diet to Improve Nutritional Outcomes in Peritoneal Dialysis Patients
|
N/A |